***Background.*** *Pseudomonas aeruginosa* is the 5th most common pathogen implicated in nosocomial infections with increasing resistance to a limited arsenal of antibiotics. Monte Carlo Simulations (MCS) provide clinicians with an additional tool to guide empiric therapy by determining the probability that an antibiotic regimen will reach a certain pharmacodynamic target to optimize bactericidal activity. This study determined which antibiotic regimens will achieve a goal probability of target attainment (PTA) of 90% against *P. aeruginosa* at our institution.

***Methods.*** This study was a retrospective review of microbiological data from first cultures positive for *P. aeruginosa* at University of Kentucky HealthCare for 2012. Minimum inhibitory concentrations (MICs) for the following antibiotics were analyzed: aztreonam, cefepime, meropenem, and piperacillin/tazobactam administered via intermittent and prolonged infusion, amikacin, gentamicin, and tobramycin. Using MICs from UKHC specific isolates, and pharmacokinetic and pharmacodynamic parameters from previously published studies, a 10,000-subject MCS was run for each antimicrobial regimen to determine PTA.

***Results.*** Two-hundred seventy two isolates were included for analysis. For studied antibiotics against *P. aeruginosa*, the MIC50/MIC90 were 8/8 mcg/mL for amikacin, 8/32 mcg/mL for aztreonam, 4/16 mcg/mL for cefepime, 2/16 mcg/mL for gentamicin, 1/8 mcg/mL for meropenem, 8/128 mcg/mL for piperacillin/tazobactam, and 2/8 mcg/mL for tobramycin. None of the tested β-lactam regimens administered over 30 minutes reached a PTA \> 90%. Three-hour infusions of cefepime 2g every 8 hours, meropenem 1g every 8 hours, and meropenem 2g every 8 hours had a PTA of 93%, 92%, and 100%, respectively. Amikacin 25 mg/kg/day had a PTA of 94%.

***Conclusion.*** In patients with kinetics similar to healthy subjects, standard doses of β-lactam antibiotics administered via intermittent infusion do no reach PD targets against *P. aeruginosa* isolates at UK HC. Amikacin 25 mg/kg/day and some prolonged infusions of β-lactams achieved PD targets against *P. aeruginosa*. There are opportunities for further study to examine the clinical application of MCS in designing empiric antimicrobial therapy.
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